Related Experiment Video
Updated: May 22, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Use of abatacept in rheumatoid arthritis
Johannes von Kempis1, Jean Dudler, Paul Hasler
1Division of Rheumatology and Rehabilitation/Department of Medicine, Kantonsspital St. Gallen, Switzerland. johannes.kempis@kssg.ch
Abstract:
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Rheumatic Heart Disease III: Medical Management
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
The JAK-STAT Signaling Pathway
